U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H20N8O2
Molecular Weight 368.3931
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MRK-016

SMILES

CN1N=CN=C1COC2=NN3C(C=NN=C3C4=NOC(C)=C4)=C2C(C)(C)C

InChI

InChIKey=QYSYOGCIDRANAR-UHFFFAOYSA-N
InChI=1S/C17H20N8O2/c1-10-6-11(23-27-10)15-21-19-7-12-14(17(2,3)4)16(22-25(12)15)26-8-13-18-9-20-24(13)5/h6-7,9H,8H2,1-5H3

HIDE SMILES / InChI

Molecular Formula C17H20N8O2
Molecular Weight 368.3931
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

MRK-016 is a selective inverse agonist of GABA receptor alpha-5 subunit. It was shown; that in animal models this compound has effect effects on depression.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.4 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
in animals: 1 mg/kg of a 1 mg/ml solution in 50% polyethylene glycol 300 was administered after overnight food deprivation to either male Sprague-Dawley rats (∼300 g; n = 6), female beagle dogs (∼12 kg; n = 3), or male rhesus monkeys (∼4 kg; n = 3)
Route of Administration: Intravenous
In Vitro Use Guide
MRK-016 is clearly an GABAA α5-selective inverse agonist, it has much greater efficacy at the α5 subtype (maximal efficacy, −55%) compared with the α1, α2, or α3 subtypes respective maximal efficacy values, −16, +6, and −9%, respectively). Most notably, however, the efficacy of MRK-016 at the α5 subtype (−55%) is greater than that observed for α5IA (−40%) and is comparable with the α5 inverse agonism of the nonselective full inverse agonist DMCM (−57%)
Substance Class Chemical
Record UNII
TXZ4DVJ9MF
Record Status Validated (UNII)
Record Version